Post‐treatment emergent adverse events in depressed patients following treatment with milnacipran and paroxetine

P. Vandel,D. Sechter,E. Weiller,N. Pezous,F. Cabanac,A. Tournoux,E. Panconi

DOI: https://doi.org/10.1002/hup.644

2004-12-01

Human Psychopharmacology

Abstract:Several selective serotonin reuptake inhibitors (SSRI), in particular paroxetine, have been reported to produce a number of post-treatment emergent adverse events following abrupt withdrawal (Black et al., 2000; Judge et al., 2002; Michelson et al., 2000). The selective serotonin and noradrenaline reuptake inhibitor (SNRI), venlafaxine, has been similarly incriminated (Pinzani et al., 2000; Trenque et al., 2002). The protocol of a recent double-blind randomized comparative trial of the SSRI, paroxetine, and the SNRI, milnacipran, in depressed outpatients (Sechter et al., 2004) called for withdrawal from the test drugs after either 6 weeks or 24 weeks treatment. We report here the results of an analysis of post-treatment adverse events resulting from these withdrawals. Patients (n1⁄4 303) suffering from a major depressive episode according to the DSM-IV, recruited at 42 centres in Western Europe, were treated for 6 weeks with paroxetine (20 mg/day) (n1⁄4 153) or milnacipran (100 mg/day, 50 mg bid) (n1⁄4 150). At the end of this period the drugs were withdrawn without tapering. Patients could, however, elect to continue treatment for a further 18 weeks. Patients were evaluated at inclusion and after 7, 14, 28 and 42 days of treatment. Those who elected to continue for a further 18 weeks were also evaluated after 84, 126 and 168 days. Both groups were evaluated 1 week after treatment discontinuation. At each assessment, antidepressant efficacy was determined by the Montgomery-Asberg depression rating scale (MADRS) and spontaneously reported adverse effects were recorded. Some 255 patients completed the 6 week treatment. The antidepressant effect of the two compounds was comparable with 62.8% and 64.9% responders (50% or greater reduction in the MADRS score) in the milnacipran and paroxetine groups respectively (p1⁄4 0.71). Both compounds were, in general, well tolerated. Similar numbers of patients in each group experienced at least one adverse event which led to premature withdrawal, 17 (11.5%) in the milnacipran-treated group and 20 (13.2%) in the paroxetinetreated group. Most of these adverse events, which were mainly gastro-intestinal in both groups and neurological (dizziness) or psychiatric (anxiety) with paroxetine, occurred at the beginning of the study (Sechter et al., 2004). Of the patients who stopped treatment after 6 weeks, 1-week follow-up data were available for 90 patients (46 milnacipran and 44 paroxetine). Six patients who stopped milnacipran (13%) and 14 patients (31.8%) who stopped paroxetine reported, respectively, 12 and 20 post-treatment emergent adverse events (Table 1). The most common events were anxiety in the milnacipran group and dizziness, anxiety, nervousness, insomnia and nightmares in the paroxetine group (Table 2). A total of 118 patients elected to continue their treatment for an additional 18 week extension phase. Of those completing this phase (thus a total treatment period of 24 weeks), 1week follow-up data were available for 53 patients (20 milnacipran; 33 paroxetine). Six patients (30%) on milnacipran and 10 patients (30.3%) on paroxetine reported, respectively, 6 and 28 post-treatment emergent events (Table 1). The most frequently reported events were anxiety in the milnacipran group and dizziness, anxiety and nausea in the paroxetine group (Table 2). Thus when given under identical double-blind conditions at equally effective doses paroxetine produced systematically more post-treatment emergent adverse events than milnacipran. This was true after both a relatively short course of treatment (6 weeks) as well as a longer (24 week) treatment period. In addition the qualitative nature of the adverse events differed between the two drugs with dizziness, anxiety and sleep disturbance (insomnia and nightmares) as the principal effects occurring with paroxetine while anxiety was the major effect reported with milnacipran (Table 2). The reason for this difference is not clear but it may relate to the dual action of milnacipran on the reuptake of noradrenaline and serotonin compared with the selective effect of paroxetine on the reuptake